WASHINGTON — In a new study, subcutaneous biweekly alirocumab, added to high-intensity statin therapy, resulted in greater coronary plaque regression in non-infarct-related arteries after 1 year in patients with acute MI.
The PACMAN-AMI study used serial, two-vessel, multimodality intracoronary imaging to assess the effects of the PCSK9 inhibitor alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis in patients with acute MI.
Among 300 patients undergoing PCI for acute MI, mean change in percent atheroma volume assessed via IVUS in non-infarct-related arteries after 52 weeks